Russell Investments Group Ltd. cut its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 2.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,348,709 shares of the biopharmaceutical company’s stock after selling 134,154 shares during the period. Russell Investments Group Ltd.’s holdings in Pfizer were worth $152,732,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Pfizer by 11.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,132,291 shares of the biopharmaceutical company’s stock worth $31,840,000 after acquiring an additional 112,523 shares during the period. Pictet Asset Management Holding SA boosted its stake in Pfizer by 62.8% in the 3rd quarter. Pictet Asset Management Holding SA now owns 4,721,719 shares of the biopharmaceutical company’s stock worth $134,667,000 after purchasing an additional 1,820,944 shares during the period. Leelyn Smith LLC increased its holdings in Pfizer by 3.9% during the 3rd quarter. Leelyn Smith LLC now owns 128,235 shares of the biopharmaceutical company’s stock worth $3,657,000 after purchasing an additional 4,851 shares in the last quarter. Verus Capital Partners LLC increased its holdings in Pfizer by 5.1% during the 3rd quarter. Verus Capital Partners LLC now owns 16,716 shares of the biopharmaceutical company’s stock worth $477,000 after purchasing an additional 805 shares in the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co acquired a new stake in shares of Pfizer in the 3rd quarter valued at about $221,000. 68.36% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on PFE shares. DZ Bank cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, November 6th. Cantor Fitzgerald lifted their target price on Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. Argus set a $40.00 target price on Pfizer in a research note on Wednesday, November 4th. Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Royal Bank Of Canada raised their price target on shares of Pfizer from $25.00 to $28.00 and gave the stock a “sector perform” rating in a research note on Wednesday, November 4th. Six investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $30.32.
Check Out Our Latest Analysis on PFE
Pfizer Trading Down 0.0%
Pfizer stock opened at $28.89 on Monday. The firm has a 50-day moving average of $28.80 and a 200-day moving average of $26.98. Pfizer Inc. has a one year low of $23.62 and a one year high of $31.44. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.42 and a quick ratio of 1.10. The company has a market cap of $164.65 billion, a price-to-earnings ratio of 41.27, a P/E/G ratio of 1.90 and a beta of 0.31.
Pfizer (NYSE:PFE – Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13. The firm had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a return on equity of 19.88% and a net margin of 6.34%. The business’s quarterly revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.87 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 3.04 earnings per share for the current fiscal year.
Pfizer Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.0%. Pfizer’s dividend payout ratio is currently 245.71%.
Pfizer Company Profile
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Recommended Stories
- Five stocks we like better than Pfizer
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
